CareDx exclusively distributing TruSight HLA

Published: 2018-05-09

On May 4, CareDx and Illumina entered into a commercial agreement which provides CareDx with the exclusive global distribution rights for TruSight HLA. Beginning on June 1, 2018, the Company will be the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product lines, and associated Assign HLA software, for use in the Field. In addition, the Company will also be granted the exclusive right to develop and commercialize the next generation (v3) of the HLA product lines for use in the Field, as well as a NGS product for chimerism detection. The Company has agreed to use its own trademarks for commercialization of the development stage HLA and chimerism products and intends using names associated with an AlloSeq branding.